This study examined the clinical course of patients with DTC who received lenvatinib treatment and investigated the specific criteria for the introduction of lenvatinib treatment in lung metastasis. The study showed that patients with lung metastasis as target lesion had significantly better prognosis regardless of other parameters. Furthermore, the median OS was good at 62.9 months in the lung metastasis group even though the median tumor size of lung metastasis at the time of lenvatinib treatment initiation was 17 mm. However, patients with lung metastasis-related findings at lenvatinib treatment initiation had a poorer prognosis. Therefore, lung metastasis-related finding was considered to be a negative prognostic factor in the lung metastasis group.
The first result of SELECT by Schlumberger et al. showed that a median progression free survival (PFS) duration following lenvatinib treatment was 18.3 months [4]. Additionally, Gianoukakis et al. revealed prolonged PFS (33.1 months) in lenvatinib responders [15]. Therefore, it is important to identify responders for predicting prognosis. Previous studies have reported that some parameters including patients’ age were associated with OS following lenvatinib treatment [5–7, 16]. However, in this study, no correlation was found between such patient’s baseline characteristics and OS. Furthermore, the factor whether lenvatinib was initiated for lung metastasis or other metastases was the only independent prognostic factor. Since patients with thyroid cancer complicated with lung metastasis had generally better prognosis than patients with other metastases such as bone [17], liver [18], and brain [19], it might be reasonable that the criteria of lenvatinib initiation are determined by each target organ.
A previous study reported that patients with a pleural effusion survived a duration of 0.1–82.8 months and pleural effusion was the prognostic factor among patients with metastatic thyroid cancer [20]. Furthermore, the events of pleural effusion may predict bad prognosis during lenvatinib treatment [21]. Our study showed that patients with lung metastasis-related finding at lenvatinib treatment initiation had a poorer prognosis than those who did not. Sugino et al. also reported that the presence of a symptom was the only factor significantly related to poorer PFS and OS following lenvatinib treatment [22]. Therefore, it is important to start lenvatinib treatment before the occurrence of lung metastasis-related findings.
The initial lenvatinib dose of 24 mg/day in patients with thyroid cancer was determined by a phase II study [23]. However, higher toxicity was observed in the SELECT, especially in the Japanese population [4, 8]. We previously investigated a small population in a preliminary study that assessed the initial low dose of lenvatinib. The study indicated that the initial low dose of lenvatinib may be allowed for patients with older age or comorbidities [12]. On the contrary, a randomized study of lenvatinib 18 mg/day vs 24 mg/day in patients with DTC revealed that a starting lenvatinib dose of 18 mg/day did not demonstrate noninferiority compared to a starting dose of 24 mg/day. Furthermore, the safety profile was comparable, with no clinically relevant difference between arms. Therefore, the study concluded that the appropriate initial dose of lenvatinib was 24 mg/day [24]. In this study, no significant difference was found in the OS by the initial dose of lenvatinib. One reason is that racial difference may affect the efficacy and metabolism of lenvatinib [25–27]. The blood plasma concentration of lenvatinib and patient characteristics may need to be considered to determine the appropriate dose [28, 29].
In the subgroup analysis of SELECT, the median OS in patients with baseline lung metastasis of ≥ 10 mm, 15 mm, and 20 mm were 44.7, 44.1, and 34.7 months, respectively [5]. The study concluded that the early initiation of lenvatinib treatment may improve outcomes in patients with radioiodine-refractory DTC and lung metastasis of ≥ 10 mm [5]. On the contrary, the result of our study showed that the median OS of the lung metastasis group was good at 62.9 months even though the median tumor size for the target lesion was 17 mm, which was larger than the size of 10 mm. Furthermore, the median duration from when the lung metastasis became 10 mm to the start of lenvatinib treatment was 22.1 (95% CI, 0–70.6) months in patients with DTC whose lung metastasis diameter at the time of diagnosis of distant metastasis was < 10 mm. Since the incidence of AE of lenvatinib was very high, especially in the Japanese population [4, 8], very early administration of lenvatinib is likely to be harmful. The difference in the results between our study and those of a previous subgroup analysis might have been due to the difference in the study population. Our study analyzed patients who received lenvatinib for the target lesion of lung metastasis. On the contrary, a previous study analyzed patients with DTC with any lung metastasis regardless of target or nontarget lesions [5]. In DTC patients with lung metastasis, it is important not only to determine lenvatinib treatment initiation simply based on the tumor size but also to consider the previous clinical course, life prognosis, and wishes of the patient.
This study has some limitations. First, this was a single-center, nonrandomized, retrospective study that included a small number of patients. Second, some baseline data of the patients were missed because those patients were initially treated in other institutions. Finally, the biomarker analysis was not performed in our study. The lung metastasis group may have better histological nature than the other metastases group [30, 31]. Despite these limitations, we believe that the results of our study contribute to the understanding of the clinical course and outcome in patients with DTC treated with lenvatinib. Our results may also contribute the information to determine the timing of lenvatinib initiation by the clinicians and for the patients who have concerns about starting tyrosine kinase inhibitor.
In conclusion, target lesion was the only independent prognostic factor of OS following lenvatinib treatment. Therefore, compared with the other metastases group, the lung metastasis group had a better prognosis regardless of their baseline characteristics. However, patients with lung metastasis-related finding at the initiation of lenvatinib treatment had a poorer prognosis among the lung metastasis group. It is important to consider not only the tumor size but also the presence of lung metastasis-related findings when initiating lenvatinib treatment for DTC patients with lung metastasis.